What is Dreem?
Founded in 2014, Dreem operates at the intersection of neuroscience and digital health. The company provides comprehensive sleep care solutions tailored for individuals, employers, and healthcare providers. With a robust portfolio of 30 patents and a scientific advisory board comprised of world-renowned neuroscientists and sleep doctors, Dreem has established itself as a research-driven entity. Its hardware is currently utilized by prestigious academic and medical institutions, including Harvard Medical School, MIT, and the Stanford Sleep Center, validating its efficacy in clinical environments. The company maintains a global footprint with operations spanning New York, Paris, and Taipei, supported by a multidisciplinary team dedicated to improving patient outcomes through data-backed sleep diagnostics.
How much funding has Dreem raised?
Dreem has raised a total of $61M across 3 funding rounds:
Unspecified
$4M
Private Equity
$22M
Private Equity
$35M
Unspecified (2016): $4M with participation from Laurent Alexandre and Xavier Niel
Private Equity (2017): $22M led by Xavier Niel, Dr. Laurent Alexandre, and MAIF
Private Equity (2018): $35M supported by Bpifrance and JJDC
Key Investors in Dreem
Bpifrance
A French public investment bank that provides credit, guarantees, and equity to support innovation and international growth for startups and mid-cap companies.
JJDC
The venture capital arm of Johnson & Johnson, focusing on innovative medical technologies, pharmaceuticals, and healthcare solutions that address critical patient needs.
MAIF
A prominent French mutual insurance company that provides diverse financial services and specialized insurance solutions to individuals and professional sectors.
What's next for Dreem?
With the recent capital injection, Dreem is well-positioned to scale its enterprise-level sleep care offerings and expand its reach within the global healthcare market. The strategic focus will likely center on deepening its integration with clinical workflows and enhancing its digital therapeutics platform to meet the growing demand for remote patient monitoring and personalized sleep interventions. As the company continues to leverage its strong relationships with institutional partners and investors, it is poised to transition from a research-heavy startup to a dominant force in the digital health ecosystem. Future growth will likely involve further commercialization of its diagnostic tools and the expansion of its clinical research initiatives to address the broader implications of sleep health on chronic disease management.
See full Dreem company page
